1.646.889.1200|info@lifescipublicrelations.com

Cancer Treatment Developer Rain Therapeutics Closes $18.4 Million Series A

//Cancer Treatment Developer Rain Therapeutics Closes $18.4 Million Series A

Cancer Treatment Developer Rain Therapeutics Closes $18.4 Million Series A

Rain Therapeutics Inc., a Fremont, Calif.-based developer of small molecule therapeutics for patients with cancer, has secured $18.4 million in Series A funding. Biotechnology Value Fund led the round, with participation from investors including Perceptive Advisors and Auckland UniServices Ltd.’s Inventors Fund.

By | 2018-06-07T14:28:22-04:00 May 21st, 2018|News|Comments Off on Cancer Treatment Developer Rain Therapeutics Closes $18.4 Million Series A

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.